Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:CMPX NASDAQ:PBYI NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.71-3.9%$1.68$1.07▼$6.18$107.37M1.16877,917 shs883,118 shsCMPXCompass Therapeutics$2.27+3.2%$3.93$1.61▼$6.88$396.19M0.797.61 million shs6.71 million shsPBYIPuma Biotechnology$7.31+0.6%$7.03$3.03▼$7.90$370.04M1.24276,343 shs154,305 shsSNDLSNDL$1.45+0.7%$1.42$1.15▼$2.89$370.65M0.882.24 million shs596,187 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+14.84%+15.28%+14.84%-67.58%-19.82%CMPXCompass Therapeutics+6.28%+21.55%-56.11%-62.65%+5.26%PBYIPuma Biotechnology+2.68%+6.75%-3.58%-5.34%+125.08%SNDLSNDL-0.69%+4.35%-4.64%-7.10%+11.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.71-3.9%$1.68$1.07▼$6.18$107.37M1.16877,917 shs883,118 shsCMPXCompass Therapeutics$2.27+3.2%$3.93$1.61▼$6.88$396.19M0.797.61 million shs6.71 million shsPBYIPuma Biotechnology$7.31+0.6%$7.03$3.03▼$7.90$370.04M1.24276,343 shs154,305 shsSNDLSNDL$1.45+0.7%$1.42$1.15▼$2.89$370.65M0.882.24 million shs596,187 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+14.84%+15.28%+14.84%-67.58%-19.82%CMPXCompass Therapeutics+6.28%+21.55%-56.11%-62.65%+5.26%PBYIPuma Biotechnology+2.68%+6.75%-3.58%-5.34%+125.08%SNDLSNDL-0.69%+4.35%-4.64%-7.10%+11.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50221.64% UpsideCMPXCompass Therapeutics 2.86Moderate Buy$13.60499.12% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/ASNDLSNDL 1.67Reduce$5.00244.83% UpsideCurrent Analyst Ratings BreakdownLatest ALDX, SNDL, CMPX, and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026ALDXAldeyra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)4/29/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/27/2026CMPXCompass Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/20/2026CMPXCompass Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026CMPXCompass Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACMPXCompass Therapeutics$850K480.95N/AN/A$1.04 per share2.18PBYIPuma Biotechnology$228.40M1.63$0.84 per share8.71$2.52 per share2.90SNDLSNDL$677.32M0.55$0.11 per share12.79$3.08 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)CMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%8/10/2026 (Estimated)PBYIPuma Biotechnology$31.11M$0.4815.2338.47N/A10.69%20.30%12.05%8/6/2026 (Estimated)SNDLSNDL-$11.29M-$0.03N/A36.25N/A-1.19%-1.02%-0.85%7/30/2026 (Estimated)Latest ALDX, SNDL, CMPX, and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A3/12/2026Q4 2025SNDLSNDL$0.01$0.0291+$0.0191$0.03$257.97 million$183.87 million3/5/2026Q4 2025CMPXCompass Therapeutics-$0.10-$0.09+$0.01-$0.09($0.90) millionN/A2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72CMPXCompass TherapeuticsN/A19.0419.04PBYIPuma BiotechnologyN/A2.382.24SNDLSNDL0.124.843.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CMPXCompass Therapeutics68.43%PBYIPuma Biotechnology61.29%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%CMPXCompass Therapeutics18.70%PBYIPuma Biotechnology22.20%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million54.53 millionOptionableCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableSNDLSNDL2,751257.40 millionN/AOptionableALDX, SNDL, CMPX, and PBYI HeadlinesRecent News About These Companies1CM Provides Update on Arrangement Agreement with SNDL4 hours ago | finance.yahoo.comSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores4 hours ago | finance.yahoo.com1CM Provides Update on Arrangement Agreement with SNDL4 hours ago | newsfilecorp.comNSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores4 hours ago | financialpost.comFSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis StoresMay 27 at 6:33 PM | globenewswire.comMay 2026's Promising Penny Stocks To ConsiderMay 25 at 5:27 PM | finance.yahoo.comTop Canadian Marijuana Stock Choices For Better Investing In 2026May 22, 2026 | marijuanastocks.comMAlliance Global Partners Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comATB Cormark Capital Markets Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | finance.yahoo.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | zacks.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | finance.yahoo.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | insidermonkey.comSNDL (NASDAQ:SNDL) Rating Lowered to "Strong Sell" at Zacks ResearchMay 1, 2026 | marketbeat.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 30, 2026 | finance.yahoo.comSNDL Quarterly Revenue Dented By Soft Liquor, Cannabis Market ConditionsApril 30, 2026 | marketwatch.comSNDL sends pot stocks lower as market headwinds drive Q1 revenue missApril 30, 2026 | msn.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comSNDL Inc. Disappoints With Declining Q1 2026 RevenueApril 30, 2026 | seekingalpha.comSNDL Inc. Earnings Call: Cost Cuts Amid Cannabis StrainApril 29, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALDX, SNDL, CMPX, and PBYI Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.71 -0.07 (-3.93%) Closing price 04:00 PM EasternExtended Trading$1.69 -0.02 (-1.17%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Compass Therapeutics NASDAQ:CMPX$2.27 +0.07 (+3.18%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.01 (+0.44%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.31 +0.04 (+0.55%) Closing price 04:00 PM EasternExtended Trading$7.30 0.00 (-0.07%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.SNDL NASDAQ:SNDL$1.45 +0.01 (+0.69%) Closing price 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
